获取途径

作者

N Wei, B Zhang, Y Wang, X H He, L C Xu, G D Li, Y H Wang, G Z Wang, H Z Huang, W T Li

作者单位

Department of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. liwentao98@12 Department of Interventional Radiology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. Department of Interventional Medical, Peoples Hospital Xintai City, Taishan Medical University, Xintai, 271200, China. Affiliations com.

刊名

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

年份

2019

卷号

Vol.21 No.4

页码

443-450

ISSN

1699-3055

关键词

Colorectal cancer Floxuridine Liver metastasis Raltitrexed Transcatheter arterial chemoembolization.

摘要

Purpose: To evaluate and compare the efficiency and safety of raltitrexed- or floxuridine -based transarterial chemoembolization in patients with unresectable colorectal cancer liver metastasis . Methods: We conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017. Of these, 61 patients received TACE using raltitrexed, oxaliplatin, and pirarubicin , and 20 received TACE using...更多

Purpose: To evaluate and compare the efficiency and safety of raltitrexed- or floxuridine -based transarterial chemoembolization in patients with unresectable colorectal cancer liver metastasis . Methods: We conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017. Of these, 61 patients received TACE using raltitrexed, oxaliplatin, and pirarubicin , and 20 received TACE using FUDR, oxaliplatin, and pirarubicin . The objective response rate , disease control rate , overall survival , progression-free survival , and adverse reactions were evaluated and compared between the two groups, and prognostic factors for OS were analyzed. Results: The ORRs of the raltitrexed group and FUDR group were 67.2 and 45.0%, respectively , and the DCRs were 86.9 and 80.0%, respectively . The median OS was 14.0 months in the raltitrexed group and 13.0 months in the FUDR group . The median PFS was 2.1 months in the raltitrexed group and 2.4 months in the FUDR group . Univariate and multivariate analyses showed that the primary tumor site, Child-Pugh class, and combination with local ablation were independent significant factors affecting survival. There were no significant differences in adverse reactions between the two groups , and no treatment-related death occurred in either group. Conclusion: TACE treatment based on raltitrexed or FUDR is an efficient and safe alternative choice for treating unresectable CRCLM.收起

文献类型

期刊

浏览量

14